DuPont de Nemours presents a distinctive profile within the specialty chemicals sector, with systematic screening revealing contradictory signals between operational health and profitability metrics. The company's current ratio of 2.42 indicates substantial short-term liquidity strength, while a conservative debt-to-equity ratio of 0.23 positions the balance sheet well below industry stress thresholds. Trading at $137.00 against a 52-week range of $86.58–$157.98, the stock sits approximately 13% below its recent peak, with a price-to-book ratio of 1.21 suggesting moderate valuation relative to stated equity value of $34.02 per share.

Fundamental strengths emerging from the screening model include:

• Gross margin of 37.23% demonstrates pricing power and cost management capabilities within commodity-exposed chemical operations
• Operating margin of 10.12% reflects operational efficiency despite challenging revenue conditions
• Beta of 1.06 indicates near-market correlation, offering cyclical exposure without excessive volatility

The research perspective highlights material headwinds through negative profitability metrics: ROE of -0.16%, ROA of -0.1%, and net margin of -0.3% with EPS of -$0.07. The 22.51% year-over-year revenue decline represents significant top-line pressure, likely reflecting broader industrial demand weakness or portfolio restructuring impacts. The absence of trailing P/E data confirms current unprofitability, while the price-to-sales ratio of 1.91 on an $18.5 billion market capitalization suggests the market maintains expectations for margin recovery.

Compared to peers Sherwin-Williams, Ecolab, and PPG Industries, DuPont's balance sheet conservatism and liquidity positioning stand out, though current profitability lags. The systematic model flags the company as transitioning through a challenging operational cycle with financial flexibility intact.